Patients with retinal diseases who were treated with anti-VEGF therapies through manufacturer patient assistance programs ...
In this Healio Video Perspective from Retina 2026, Sharon Fekrat, MD, FACS, FASRS, of Duke University, discusses the current ...
Wet age-related macular degeneration (wet AMD) is a progressive eye disease in which abnormal, fragile blood vessels grow ...
AbbVie and RemeGen are collaborating on RC148, a novel PD-1/VEGF-targeted bispecific antibody already being developed as a ...
Zacks Investment Research on MSN
Is BMY's deep pipeline the key to its next growth phase?
Bristol Myers Squibb BMY highlighted the potential of its deep and promising pipeline at the 44th Annual J.P. Morgan ...
Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class Non-VEGF-Targeted Therapeutics for Wet AMD ...
Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...
AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...
The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...
A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The drug also showed potential efficacy in patients who failed to optimally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results